TLX trades 88.3% below Wall Street's consensus target of $19.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TLX achieves its forward estimates and maintains a stable P/E multiple of 171.0x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Telix Pharmaceuticals Limited (TLX) has a Wall Street consensus price target of $19.00, based on estimates from 5 covering analysts. With the stock currently trading at $10.00, this represents a potential upside of +88.3%. The company has a market capitalization of $3.39B.
Analyst price targets range from a low of $17.00 to a high of $20.00, representing a 16% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TLX trades at a trailing P/E of -455.3x and forward P/E of 171.0x. Analysts expect EPS to grow -69.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.49, with bear and bull scenarios of $12.91 and $27.00 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EXELExelixis, Inc. | $13.0B | $51.35 | $47.33 | -8.8% | Buy | 14.7x | 32 |
RNWReNew Energy Global Plc | $2.3B | $6.43 | $6.39 | +1.1% | Buy | 0.5x | 6 |
AGENAgenus Inc. | $127M | $3.04 | $7.33 | +144.3% | Buy | 3.8x | 11 |
LNTHLantheus Holdings, Inc. | $6.9B | $106.13 | $108.50 | +4.5% | Buy | 19.4x | 17 |
NVSNovartis AG | $284.2B | $148.93 | $170.00 | +15.6% | Hold | 16.9x | 25 |
BMYBristol-Myers Squibb Company | $111.7B | $54.70 | $62.60 | +15.9% | Hold | 8.5x | 41 |
PRAXPraxis Precision Medicines, Inc. | $8.8B | $303.00 | $584.00 | +106.9% | Buy | — | 16 |
GEGE Aerospace | $371.0B | $355.12 | $380.14 | +6.3% | Buy | 47.4x | 34 |
GEHCGE HealthCare Technologies Inc. | $27.6B | $60.64 | $81.10 | +31.7% | Buy | 12.6x | 18 |
SYKStryker Corporation | $116.8B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
Quick answers to the most common questions about buying TLX stock.
The consensus Wall Street price target for TLX is $19, representing 88.3% upside from the current price of $10. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TLX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 88.3% upside from current levels.
At a forward P/E of 171.0169x, TLX trades at a premium valuation. The consensus price target of $19 (88.3% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $20 for TLX, while the most conservative target is $17. The consensus of $19 represents the median expectation. Our quantitative valuation model projects a bull case target of $27 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TLX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TLX stock forecast based on 5 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $17 (bear case) to $20 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $20, with bear/bull scenarios of $13/$27.
Our quantitative valuation model calculates TLX's fair value at $20 (base case), with a bear case of $13 and bull case of $27. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
TLX trades at a forward P/E ratio of 171.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TLX, with a "Buy" consensus rating and $19 price target (88.3% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TLX analyst price targets range from $17 to $20, a 16% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground. Our model's $13-$27 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.